InspireMD, Inc. closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share, and pre-funded…

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on November 16, 2026, InspireMD, Inc. (the “ Company ”) closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), and pre-funded warrants to

Event · Offering · closed
Instrument
shares of the Company’s common stock, par value $0.0001 per share
Gross proceeds
approximately $34.9 million in net proceeds
Shares
7,342,308 shares
Also in this documentOffering · $5.3M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 20, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$NSPR
Neutral
medium confidence
Mentioned
$NSPR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NSPRNeutralMed
01

Why it matters

Completion of the base offering plus full exercise of the underwriter option finalizes the total capital raised and confirms the near-term dilution overhang from the additional shares and warrants.

02

Market read

Traders can update positioning for dilution risk and financing overhang now that the option exercise and final closing are confirmed in a primary SEC filing.

03

What to watch

Warrant strike prices and the effective dilution per share are not detailed here; traders may need the prospectus/supplement to assess overhang versus runway benefit.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Nov 20, 2026 confirming final closing and option exercise

Background

The company used an effective automatic shelf registration (Form S-3) to issue common stock, pre-funded warrants, and accompanying Series L warrants, with an underwriter option exercisable within 30 days.

Company-level read

Ticker impact

$NSPRNeutralMedium confidence
Context

InspireMD closed its shelf offering, selling 7.34M shares plus warrants, and then exercised an underwriter option adding about $5.3M net proceeds.

Expected impact

Likely mild downside or volatility as the market prices the additional dilution from the option exercise, partially offset by the net cash proceeds.

Evidence & confidence

The filing is a primary disclosure of completed equity issuance and warrant terms, but it does not include guidance or a valuation anchor that would drive a large directional repricing by itself.

Market effects

Adds to the broader pattern of small-cap biotech/medtech using shelf offerings and warrant structures for funding.

No direct regional spillover beyond US small-cap risk appetite.

Limited, company-specific capital-raise disclosure with no stated cross-border operational impact.

Counterpoint

If the company’s cash runway is the key constraint, the incremental $5.3M net proceeds could reduce financing risk and support the stock on dips.

Key entities

  • InspireMD, Inc.

    Subject of the 8-K, closing a shelf offering and the underwriter option on Nov 20, 2026.

  • Lake Street Capital Markets, LLC

    Representative for the underwriters that exercised the option in full.

  • Securities Transfer Corporation

    Warrant agent under the warrant agency agreement dated Nov 12, 2026.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to